Subsequently, the positive results from the BEACON CRC (colorectal cancer) trial led the FDA to approve, in 2020, the combination of encorafenib and cetuximab (an anti-EGFR monoclonal antibody) in the setting of pretreated BRAF V600E mutant patients with metastatic colorectal cancer [58]. Here, BRAF is linked to metastatic colorectal cancer.